Ken Shinomiya Becomes Leader of Asahi Kasei’s Healthcare Sector
Leading the way for the sector’s continued growth and commitment to improving patient outcomes
Ken Shinomiya, Leader of Asahi Kasei’s Healthcare Sector
Having served as Vice President of Strategy at ZOLL Medical Corporation from fiscal 2016 to fiscal 2017, Shinomiya became Head of the Bioprocess Division of Asahi Kasei Medical in April 2019 and President of Asahi Kasei Medical in April 2023. In April 2025, he was named President of Asahi Kasei Life Science, the successor company to the bioprocess business of Asahi Kasei Medical. With operations focused on products and services that support the manufacture of pharmaceuticals, the life science business has grown globally by ascertaining market needs and business opportunities within the pharmaceutical industry. Under Shinomiya’s leadership, the life science business has successfully expanded from its foundational Planova™ virus removal filters through the addition of contract research organization (CRO) testing services as well as the biologics contract development and manufacturing organization (CDMO) business of Bionova Scientific in the
Asahi Kasei’s Healthcare Sector has dramatically globalized since the 2012 acquisition of ZOLL Medical Corporation with its
Under the new leadership, the Healthcare Sector will continue to execute a long-term strategy to grow its pharmaceutical, life science, and critical care businesses. Guided by its mission to “Improve and save patients’ lives,” the sector is committed to delivering innovative therapeutics and medical devices that address unmet medical needs and contribute to better patient outcomes worldwide. It will serve as the main growth driver of the Asahi Kasei Group, targeting operating income of
“For over a century, the Asahi Kasei Group has created distinctive business models leveraging creativity and innovation to provide exceptional products and services to the world,” said Ken Shinomiya, Leader of Asahi Kasei’s Healthcare Sector. “Our healthcare business exemplifies Asahi Kasei’s unique ability to effectively integrate the advanced, efficiency-oriented management approaches gained through global acquisitions. Moving forward, we will further evolve based on our blended international outlook as we continue to lead the growth and globalization of the Asahi Kasei Group.”
About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 49,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Material, Homes, and Healthcare. Its Healthcare operations include devices and systems for critical care, products and services for the manufacture of biotherapeutics, and a growing portfolio of specialty pharmaceuticals. For more information, visit www.asahi-kasei.com.
Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424681712/en/
North America Contact:
Asahi Kasei America Inc.
Christian OKeefe
christian.okeefe@ak-america.com
Europe Contact:
Asahi Kasei Europe GmbH
Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu
Source: Asahi Kasei Corp.
